ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -3.34% in last session and finished the day at $8.69. Traded volume was 1,200.00 shares in the last session and the average volume of the stock remained 26.48 million shares. The beta of the stock remained 1.64. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), is a biopharmaceutical engaged in the production of development-stage products. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) rose 0.00% to $1.35 yesterday on volume of 0.00 shares. The intra-day range of the stock was $1.31 – $1.42. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has a market capitalization of 176.13 million.

The company’s stock price has risen over 40% this year, while the broad market remained somewhat flat. But, there’s trouble on the horizon. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on February 28, 2014 reported a lower of -1.03% to the closing price of $82.79. Its fifty two weeks range is $42.38 – $84.88. The total market capitalization recorded 126.99 billion. The overall volume in the last trading session was 200.00 shares. In its share capital, Gilead Sciences, Inc. (NASDAQ:GILD) has 1.53 billion outstanding shares.

MannKind Corporation (NASDAQ:MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced that it will present at upcoming conferences. On Friday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -3.13% to close the day at $6.19. Company return on investment (ROI) is – and its monthly performance is recorded as 15.70%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 23.31%.